Tag Archives: Astellas

Gilead Buys CV Therapeutics (Update 1)

By Walter Armstrong | Published: March 16, 2009
The morning’s other big M&A news comes out of the Bay Area biotech industry, where Gilead Sciences announced that it will purchase CV Therapeutics for $1.4 billion. The sudden move frees Palo Alto-based cardiovascular company CV Therapeutics from the hostile embrace of Astellas Pharma, ending a messy $1.1 billion takeover attempt. With the acquisition, Gilead, [...]
Posted in Deals | Also tagged , , , , , , | 1 Comment

Astellas Keeps After CV Therapeutics

By Cassandra Blohowiak | Published: February 27, 2009
Astellas bid for CV Therapeutics turned hostile this morning when the Japanese drug firm offered $1 billion dollars for the company directly to shareholders. The CVT board rejected Astellas’s second proposal last Friday stating that the Astellas proposal undervalued the company and is not in the best interest of the shareholders. In a press release issued this [...]
Posted in Deals | Also tagged , , , , , , | Leave a comment